The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.

The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.

Provided are biocompatible topical compositions including a novel combination of an inflammatory management agent, a vascular repair agent, a neurogenic agent, a sebum suppression agent and an exfoliating agent. Also provided are methods for treating, preventing or ameliorating rosacea, a symptom thereof or a condition related thereto by administering the biocompatible topical compositions describe herein.

Provided are biocompatible topical compositions including a novel combination of an inflammatory management agent, a vascular repair agent, a neurogenic agent, a sebum suppression agent and an exfoliating agent. Also provided are methods for treating, preventing or ameliorating rosacea, a symptom thereof or a condition related thereto by administering the biocompatible topical compositions describe herein.